XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Colon Channel
subscribe to Colon newsletter

Latest Research : Cancer : Colon

   DISCUSS   |   EMAIL   |   PRINT
Chemotherapy options improve for patients with advanced colorectal cancer
Jun 7, 2005, 11:59, Reviewed by: Dr.

"This study for the first time shows that an oral based Cap/Ox regimen is able to substitute for the complex intravenous 5-FU 2-drug- or 3-drug-combination in colorectal cancer. Large trials are underway to definitely answer this question with several thousand patients; however, the results of these studies will not be available before 2006,"

 
For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC). The findings are reported today at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

"We conducted this phase III study because the combination of oral capecitabine and oxaliplatin showed promising effects in different phase II studies. The idea of this study was to look whether CAPOX can replace the standard treatment of iv. 5-FU/folinic acid in patients with MCRC", said lead author Dr. Hendrik-Tobias Arkenau, from Clinic Bremen East in Germany.

From 2002 to 2004, the authors randomly assigned 476 patients who had not undergone previous chemotherapy to receive either FUFOX (5-fluorouracil (5-FU) 2000mg/m≤ 24h infusion, folinic acid 500mg/m≤, oxaliplatin 50mg/m≤ d1,8,15,22; q5 wks) or CAPOX (capecitabine 1000mg/m≤ bid d1-14, oxaliplatin 70mg/m≤ d1 and 8; q3 wks).

So far, based on an analysis of 2541 treatment cycles (1026 FUFOX, 1515 CAPOX), both regimens are comparably toxic and showed similar response rates (ITT-RR: 50% FUFOX and 47% CAPOX, p=NS).

Median length of time without progression of disease was 34.7 weeks in the FUFOX arm and 30.3 weeks in the CAPOX arm, respectively, a difference that was not statistically different (p=0.1), the authors found. Additionally, both treatment arms showed similar overall survival, FUFOX 74.9 weeks and CAPOX 70.9 weeks, p=0.72.

The authors conclude that CAPOX shows comparable efficacy and toxicity profiles compared to the FUFOX regimen in patients chemonaive MCRC.

"This study is important for patients because the CAPOX regimen is more convenient to administer. Patients will appreciate needing to come only twice in three weeks as outpatients to receive the 2 hourly oxaliplatin dose. Especially in the palliative setting of MCRC, patients gain more autonomy and improved quality of life," Dr. Arkenau said.

"We hope that oral capecitabine plus oxaliplatin will become the new standard treatment in first-line treatment for patients with metastatic colorectal carcinoma."

Commenting on the study, Professor Hans Joachim Schmoll of Martin-Luther-Universitšt Halle-Wittenberg in Germany said the results of the trial "are of major importance for the clinical routine, at least for those patients who would like to avoid intravenous infusional protocols, ports and pumps."

The 5-FU-infusion in combination with cytostatic agents like oxaliplatin or irinotecan in patients with colorectal cancer is complicated and needs support and a pump for the patient, he said. This is a cause of major discomfort, meaning it is important to investigate alternatives substituting the infusion of 5-FU by oral agents.

"This study for the first time shows that an oral based Cap/Ox regimen is able to substitute for the complex intravenous 5-FU 2-drug- or 3-drug-combination in colorectal cancer. Large trials are underway to definitely answer this question with several thousand patients; however, the results of these studies will not be available before 2006," Professor Schmoll said.
 

- European Society for Medical Oncology
 

http://www.esmo.org/

 
Subscribe to Colon Newsletter
E-mail Address:

 



Related Colon News

Regular aerobics protects men from colon cancer
Role for MicroRNAs in Oxygenation, Nourishing of Colon Tumors
New genetic test to spotlight heightened bowel cancer risk
$2.6 million in grants for metastatic colon cancer research
NSAIDs don't reduce colorectal cancer risk in chronic smokers
Timing of radiation treatments for colon cancer may need adjusting
How growth hormone therapy can lead to colon polyps
Review study sets treatment standard for elderly with colon cancer
Eating red meat could damage DNA by N-nitrosocompounds
Diet pattern may effect the development of colon cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us